Skip to Content

Research

Clinical Research Program

This is a list of clinical trials and research protocols underway that will help us study thryoid malignancies and other endocrine neoplasias. If you would like to participate in one of the trials, please call the Information Line toll-free at 1-800-392-1611 or askMDAnderson at 1-877-632-6789. For information on other clinical trials, please visit MD Anderson's Clinical Trials Web site.

  Click here for the latest version of the Department of Endocrine Neoplasia and Hormonal Disorder's Clinical Trials Flyer (PDF)

Last Updated: May 13, 2015

Thyroid Cancer

Protocol 2012-0471: A Pharmacodynamic study of vemurafenib in the neoadjuvant setting in patients with locally advanced thyroid cancer.
The goal of this clinical research study is to learn about how vemurafenib may affect certain biomarkers in patients with papillary thyroid cancer.

Protocol 2012-0349: A Randomized Phase 2 Study of single agent GSK2118436 (BRAFi) vs. combination regimen GSK 2118436 (BRAFi) and GSK 1120212 (MEKi) in patients with BRAF mutated thyroid carcinoma.
The goal of this clinical research study is to identify which regimen is more promising for subsequent testing in a phase III trial for BRAF mutated thyroid carcinoma.

Protocol 2015-0003: A Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
The goal of this clinical research study is to determine the response rate at 6 months following treatment with 131I in combination with placebo or selumetinib for radioactive iodine avid (RAIA) recurrent and/or metastatic thyroid cancer. 

Protocol 2103-0220: A Phase II Study of Cabozantanib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer who Progressed on First-Line VEGFR-Targeted Therapy.
The goal of this clinical research study is to learn if cabozantanib can control patients with radioiodine-refreactory differentiated thyroid cancer

Protocol 2013-0383: a Phase II Study of Pioglitazone in Follicular Patterned Thyroid Cancers that contain the PAX8-PPARgama Fusion Gene.
The goal of this clinical research study is to determine the overall response rates of patients with PAX8-PPARgama fusion gene-positive follicular-patterned thyroid carcinomas treated with pioglitazone. 

Protocol 2013-0918: A Phase II, Open-label, Study in Subjects with BRAF V600E-mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib.
The goal of this clinical research study is to learn if the combination of dabrafenib and trametinib can help to control the disease in patients with cancers, including anaplastic thyroid cancer, that are caused by a problem in a gene called BRAF V600E. 

Pituitary Tumors

Protocol 2005-0222: ACROSTUDY - A Multicenter, Post Marketing Surveillance Study of Somavert Therapy in Patients with Acromegaly in the US and Europe.
The goal of this clinical research study is to look at the safety and effectiveness of long-term pegvisomant treatment for acromegaly

Other Endocrine Neoplasias, Including Solid Tumors

Protocol 2015-0129: An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations.
The goal of this clinical research study is to determine the antitumor activity of tipifarnib in subjects with locally advanced unresectable or metastatic, relapsed, and/or refractory, non-hematological malignancies with HRAS mutations.

Protocol 2014-0081: A Pilot Study to Evaluate the Effects of Cabozantinib in Patients with Unresectable Metastatic Pheochromocytomas and Paragangliomas
The goal of this clinical research study is to learn if cabozantinib can help to control advanced or metastatic pheochromocytoma or paraganglioma.

Protocol 2009-0210: A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane 131I in Patients with Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
The goal of this clinical research study is to learn if Ultratrace Iobenguane 131I can help reduce the amount of or allow you to stop taking blood pressure drugs because of the cancer and if this drug is useful as a treatment for the cancer.

Protocol 2012-0223: A Phase II Study of Pazopanib (GW786034) in Patients with Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma.
The goal of this clinical research study is to learn if Votrient (pazopanib) can help to control metastatic pheochromocytoma or paraganglioma.

Other MD Anderson Clinical Trials Relevant to Endocrine Neoplasia Patients

Protocol 2011-0530 - A Phase I Study Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma.  The goal of this clinical research study is to find the highest tolerable dose levels of pazopanib and GSK1120212 that can be given in combination to patients with advanced cancers 

RTOG0912 - A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo for the Treatment of Anaplastic Thyroid Cancer
The goal of this Phase II clinical research study is to learn if adding pazopanib to paclitaxel and radiation (chemoradiotherapy) is safe and tolerable. 

Protocol 2013-0160 - A Phase I/II Clinical Trial evaluating DCVax-Direct, Autologous activated dendritic cells for intratumoral injection, in patients with solid tumors.
The goal of Phase II clinical research study is to find the highest tolerable dose of DCVax-Direct that can be given to patients with a locally advanced or metastatic solid tumor cancer. The goal of Phase II of this study is to learn about the safety of DCVx-Direct and learn if it can help to control the disease by causing an immune response against the cancer cells. 

Protocol 2011-0530 - A Phase 1 Study of Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGR/PDGFR/Raf inhibior, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma.
The goal of this clinical research study is to find the highest tolerable dose levels of pazopanib and GSK1120212 that can be given in combination to patients with advanced cancer. 

 

The Rolanette and Berdon Lawrence Bone Disease Program of Texas

The Rolanette and Berdon Lawrence Bone Disease Program of Texas utilizes the high quality research and clinical programs of MD Anderson Cancer Center and Baylor College of Medicine to improve early and more accurate diagnosis, treatment and prevention of bone diseases such as osteoporosis and bone metastases afflicting the people of Texas. 

Basic and Translational Research Program

Cote Laboratory.maintains a specific interest in tumors deriving from the parafollicular cell, known as medullary thyroid carcinomas (MTC).

Hofmann Laboratory studies the biology of male germ line stem cells, which are precursors of sperm cells, and the influence of their cellular microenvironment on the fate of these cells during development and disease.


© 2015 The University of Texas MD Anderson Cancer Center